John Flaherty, PharmD
Gilead Sciences
8
0
8
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Pablo Tebas, MD
University of Pennsylvania
Shared therapeutic areas:
Eric Bellissant, MD, PhD
Rennes University Hospital
Shared therapeutic areas:
Liang Peng, Doctor
Third Affiliated Hospital, Sun Yat-Sen University
Shared therapeutic areas:
François Raffi, PHD
Hopital Hotel Dieu Nantes
Shared therapeutic areas:
Huiwen Song
Sanming First Hospital
Shared therapeutic areas:
Gilles Pichancourt
CH Henri Duffaut Avignon
Shared therapeutic areas:
Yongfeng Yang
The Second Hospital of Nanjing Medical University
Shared therapeutic areas:
Ping Li
Tianjin Second People's Hospital
Shared therapeutic areas:
Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Ming Li
No.2 People's Hospital of Fuyang City
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan
All 8 trials loaded